Date: 2014-09-04
Type of information: Results
phase: preclinical
Announcement: preclinical results
Company: Sirona Biochem (Canada - France) Wanbang Biopharmaceuticals (China)
Product: SBM-TFC-039
Action
mechanism: SBM-TFC-039 is a SGLT2 Inhibitor. SGLT2 (Sodium-glucose co-transporter 2) is a protein in humans that facilitates glucose reabsorption in the kidney. SGLT2 inhibitors can block the reabsorption of glucose in the kidney, increase glucose excretion, and lower blood glucose levels. Three SGLT2 inhibitors, canagliflozine (Invokana®), dapaglifozine (Forxiga®) and empagliflozin (Jardiance®) have been already approved.
Disease: type 2 diabetes
Therapeutic area: Metabolic diseases
Country:
Trial details:
Latest
news: * On September 3, 2014, Sirona Biochem announced that Wanbang Biopharmaceuticals has successfully completed another study in the pre-clinical validation of its anti-diabetic SGLT2 Inhibitor, SBM-TFC-039, for the treatment of Type 2 diabetes. The pharmacokinetic (PK) study of SBM-TFC-039 confirms an excellent oral bioavailability of SBM-TFC-039. Bioavailability refers to the drug\'s ability to be absorbed into the body. The results are in accordance with results of an earlier study conducted by Sirona Biochem. The drug was administered as a single dose in SD rats. The first milestone of the license agreement with Wanbang Biopharmaceuticals is expected after the next scheduled study, assessing toxicology in rats during a 14 day test. This will trigger a second payment to Sirona from Wanbang Biopharmaceuticals as part of the $9.5M in upfront and milestone payments.
